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AbsTrACT
Objectives a blood-based biomarker of neuronal 
damage in sporadic creutzfeldt-Jakob disease (scJD) 
will be extremely valuable for both clinical practice and 
research aiming to develop effective therapies.
Methods We used an ultrasensitive immunoassay 
to measure two candidate biomarkers, tau and 
neurofilament light (NfL), in serum from patients with 
scJD and healthy controls. We tested longitudinal 
sample sets from six patients to investigate changes over 
time, and examined correlations with rate of disease 
progression and associations with known phenotype 
modifiers.
results serum concentrations of both tau and NfL 
were increased in patients with scJD. NfL distinguished 
patients from controls with 100% sensitivity and 100% 
specificity. Tau did so with 91% sensitivity and 83% 
specificity. Both tau and NfL appeared to increase over 
time in individual patients, particularly in those with 
several samples tested late in their disease. Tau, but 
not NfL, was positively correlated with rate of disease 
progression, and was particularly increased in patients 
homozygous for methionine at codon 129 of PRNP.
Conclusions These findings independently replicate 
other recent studies using similar methods and offer 
novel insights. They show clear promise for these blood-
based biomarkers in prion disease. Future work should 
aim to fully establish their potential roles for monitoring 
disease progression and response to therapies.
INTrOduCTION
Sporadic Creutzfeldt-Jakob disease (sCJD), the 
most common human prion disease, is a progres-
sive and fatal neurodegenerative condition, for 
which no proven disease-modifying treatment is 
currently available. Several clinical trials have been 
performed,1–4 other compounds are in preclinical 
development5 and humanised anti-prion protein 
monoclonal antibodies have been developed for 
clinical use,6 7 but there are a number of major chal-
lenges to the design of therapeutic trials in sCJD.
The illness is rapidly progressive and clinically 
heterogeneous, making the design and implemen-
tation of clinical outcome measures challenging. 
However, progress has been made with designing 
optimised outcome measures8 and using stratifica-
tion to reduce the impact of heterogeneity.9 Patients 
are often only diagnosed (and offered enrolment 
into clinical research) at an advanced stage of 
disease, by which time therapeutic agents may have 
less potential for benefit. Currently available labo-
ratory biomarkers of sCJD are based on analysis of 
cerebrospinal fluid (CSF),10 11 limiting their poten-
tial for serial measurement due to the requirement 
for lumbar puncture.
A blood-based laboratory biomarker could 
address several of these challenges. It may allow 
early identification of potential cases before more 
involved and invasive investigations have been 
performed (eg, MRI, lumbar puncture). It may be 
able to complement clinical outcome measures by 
demonstrating a biological effect of a therapeutic 
agent with greater power, allowing better deci-
sion-making about advancing from early to larger 
clinical trials.
Historically, laboratory methods for diagnosing 
sCJD have relied on intraneuronal proteins that can 
be detected in the CSF when there is rapid neuro-
degeneration: the 14-3-3 protein and more recently 
tau.10 12 However, these have now been largely 
superseded by methods based on in vitro seeded 
protein misfolding, particularly the real-time quak-
ing-induced conversion assay.11 This has been 
shown to have a sensitivity of between 80% and 
91% and specificity of between 98% and 100% for 
sCJD in different studies,13–15 although the levels 
of seeding activity would be predicted to be largely 
invariant in the latter stages of disease,16 17 so its 
utility as a progression biomarker may be limited.
Measurement of brain-derived proteins in blood 
as potential biomarkers of neurodegeneration has 
been limited by their very low concentrations, often 
below the limit of detection of standard ELISA and 
other available assay methods. Recently, however, 
the use of novel ultrasensitive assay techniques, 
such as the single molecule array (Simoa) plat-
form (Quanterix, Boston, MA, USA), has allowed 
measurement of such proteins in blood with limits 
of detection well below physiological concentra-
tions seen in healthy controls, and this has provided 
valuable new biomarkers with emerging diagnostic, 
prognostic and therapy-monitoring roles in a range 
of different diseases.18–26
Tau is an intraneuronal, microtubule-associ-
ated protein, which can be released when there 
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is neuronal damage, and also plays a more specific role in 
the pathogenesis of various neurodegenerative conditions.27 
Its concentration is known to be markedly increased in the 
CSF of patients with sCJD, and this correlates with markers 
of disease severity.28 A small study using a standard ELISA to 
measure serum tau suggested an increase in sCJD compared with 
controls.29 Its concentration in blood, measured using Simoa, 
has now been shown to have potential as a biomarker in Alzhei-
mer’s disease,18–20 as well as in non-degenerative conditions such 
as hypoxic and traumatic brain injury.21 22
The neurofilament light (NfL) chain is a component of the 
neuronal cytoskeleton. It is released by neuronal, and particu-
larly axonal, damage in a number of diseases, and its concentra-
tion can be measured in the CSF, and in blood using Simoa. It has 
been shown to have a role as a biomarker in diseases including 
frontotemporal dementia (where concentrations in CSF and 
serum correlate with clinical and radiological measures of disease 
‘intensity’)23 24 and multiple sclerosis (where its concentration in 
CSF and possibly in blood has a role in monitoring subclinical 
disease activity during disease-modifying treatment).25 26
In this study, we selected these two candidate blood-based 
biomarkers, tau and NfL, and used the Simoa platform to 
measure their concentrations in serum samples from patients 
with sCJD and from healthy control volunteers.
All of the patients included in this study were also enrolled 
in the National Prion Monitoring Cohort, a large prospective 
natural history study. Using clinical rating scale data collected 
through this study, we have developed and validated a bespoke 
rating scale that measures functional decline in patients with 
sCJD (the MRC Prion Disease Rating Scale (‘MRC Scale’)),8 
and used this to model linear slopes of functional decline for 
individual patients.9 This allows us to analyse for correlations 
between biomarkers and rate of clinical disease progression.
Recently, two other groups have reported studies using 
Simoa to measure tau and NfL in blood in cohorts including 
patients with sCJD.30 31 These included 33 and 65 patients with 
sCJD, respectively. Both showed that the concentrations of 
both proteins were elevated in patients with sCJD relative to 
controls. This provides the opportunity for direct comparison 
with our results, with the potential for independent replication 
of findings which is particularly important given the relatively 
small size of the individual studies. We also extend the analysis 
by including longitudinal samples from six patients with sCJD, 
spanning between 49 and 685 days in individual patients, to 
explore changes over time during the disease process.
MeThOds
Patients, samples and clinical data
Serum samples from 45 patients with sCJD and 24 healthy control 
volunteers were tested. All cases and controls were enrolled in 
the National Prion Monitoring Cohort,8 and samples were taken 
at the time of clinical research assessments for that study, using 
standardised methods for venepuncture, transport, fraction-
ation and storage. Samples were stored at −80°C, and thawed 
immediately prior to testing. All sCJD cases had either definite 
or probable sCJD, according to standard diagnostic criteria.12 
Healthy volunteers were friends, spouses or relatives of patients. 
Demographic and basic clinical information about the cases and 
controls is given in table 1. The ‘MRC Scale’ gives a measure 
of disease severity at the time each sample was taken, running 
from 20 (no significant impairment of function) to 0 (severely 
impaired, bedbound, unable to communicate or swallow).8 We 
have used linear mixed modelling of MRC Scale data to model 
functional decline in patients with sCJD, and we can use this 
to derive a slope coefficient representing the percentage loss 
of function per day for an individual patient. The full methods 
for this are reported elsewhere.9 Modelled slopes of decline 
calculated in this way are available for 23 of the patients with 
sCJD included in this biomarker study (the others were already 
at a very advanced stage of functional impairment at their first 
assessment, making modelling of a meaningful slope impossible).
A further 16 samples from six of these patients (giving serial 
sample sets of between two and five samples) were also tested 
to explore changes in the protein concentrations over time in 
individual patients. Only the earliest available sample from each 
patient was included in the main comparison of patients with 
controls.
Measurement of tau and NfL concentrations
The Simoa HD-1 analyser platform (Quanterix) was used to 
measure tau and NfL concentrations using the manufacturer’s 
tau and NfL reagent kits and according to the manufactur-
er’s instructions. Samples were introduced into the analyser in 
96-well plates, sealed with a preperforated ‘X-Pierce’ film (Excel 
Scientific) to reduce the chance of spillage or aerosol formation.
In the analyser, patient serum samples are diluted fourfold and 
then incubated with paramagnetic beads coated with anti-tau or 
anti-NfL antibodies and biotinylated detector antibodies. Beads 
are then washed and combined with a conjugate of streptavi-
din-β-galactosidase. This enzyme binds to the biotinylated anti-
bodies, labelling the captured protein molecules of interest. 
After being washed again, the beads are suspended in a resoru-
fin-β-D-galactopyranoside (RGP) substrate and transferred into 
Table 1 Demographic and clinical information for patients with sCJD 
and healthy controls included in the study
Patients with sCJd healthy controls
N 45 24
Diagnosis 
  Definite 40 –
  Probable 5 – 
PRNP  codon 129 
  MM 21 – 
  MV 15 – 
  VV 7 – 
  Not tested 2 – 
Age (at first sample) (n=45) 
  Mean 61.3 50.3
  SD 8.29 10.34
  Range 41.3–81.8 33.7–68.0
Gender 
  Male 22 14
  Female 23 10
MRC Scale  (n=45)
  Median 5 20
  Range 0–19 20–20
 Days after reported symptom onset (n=45) 
  Median 136 – 
  Range 45–862 – 
  Days before death  (n=44) 
  Median 18.5 – 
  Range 0–1120 – 
MRC Scale, MRC Prion Disease Rating Scale; sCJD, sporadic Creutzfeldt-Jakob 
disease. 
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an array of microwells, with individual beads being sealed within 
individual microwells. If the enzyme-labelled protein of interest 
is bound to a bead it hydrolyses RGP and produces sufficient 
fluorescent signal to be detected by the analyser, even if only 
a single molecule is bound. The analyser measures the propor-
tion of ‘positive’ wells containing beads bound to at least one 
molecule of interest (giving a ‘digital’ output proportional to the 
amount of the protein of interest in the sample when it is at 
low concentrations) and also the total fluorescent signal from all 
wells (giving an ‘analogue’ output proportional to the amount of 
the protein of interest present in the sample when it is at higher 
concentrations).
A calibration series containing known concentrations of the 
protein of interest, spanning both the ‘digital’ and ‘analogue’ 
ranges, is tested alongside the test samples. A four-parameter 
logistic curve fit data reduction method is used to generate a 
calibration curve, which is then used to calculate concentrations 
of the protein of interest in the test samples.
Quality control
Samples were tested in duplicate (two aliquots automatically 
aspirated from a single plate well), and the average of the two 
readings was used for analysis.
For the tau assay, the mean coefficient of variation (CV) 
between duplicates was 4.6%. In a subset of 16 samples only 
a single measurement was produced (technical data from the 
analyser showed that it had failed to aspirate a second aliquot 
correctly). As the variation between duplicate readings for other 
samples was very low, and the technical data identified no prob-
lems with the individual measurements from these samples, they 
were included in the analysis. All samples were tested from a 
single plate.
For the NfL assay, the mean CV between duplicates was 4.7%. 
Duplicate measurements were obtained for all samples. Samples 
were split between two plates and processed together in a single 
analyser run using the same reagents. sCJD and control samples 
were randomly distributed across both plates. All serial sample 
sets from individual patients with sCJD were tested on the same 
plate to reduce the impact of any minor variation between 
plates. Two control samples of known NfL concentration (10 and 
200 pg/mL) were included on both plates and compared (CVs of 
15% and 11%, respectively).
statistical analysis
Data were analysed using Microsoft Excel and SPSS. (V22.0) 
Neither tau nor NfL was normally distributed (Kolmogor-
ov-Smirnov tests, P<0.05). If natural log transformation was 
applied, log-tau and log-NfL were both plausibly normally 
distributed within the control group and within the sCJD group 
(Kolmogorov-Smirnov tests, P>0.05). We therefore analysed 
raw values using non-parametric statistics and log-transformed 
values using parametric statistics. Specific tests are given below.
resuLTs
Tau
Tau concentrations were higher in patients with sCJD than in 
healthy controls: median 6.22 pg/mL vs 1.56 pg/mL (Mann-
Whitney U test, P<0.001; table 2, figure 1A). Linear regres-
sion modelling of the effect of diagnosis (sCJD vs control), age 
and gender on log-tau showed a strong independent effect of 
sCJD diagnosis after adjustment for age and gender (β=0.551, 
P<0.001. r2 for model 0.345). Neither age nor gender had inde-
pendent effects (P=0.95 and P=0.1 respectively).
Tau concentrations were higher in patients with sCJD homo-
zygous for methionine at codon 129 of PRNP than in other 
genotypes: median 19.6 pg/mL in MM, 3.27 pg/mL in MV and 
4.05 pg/mL in VV groups (table 2, figure 1C). On linear regres-
sion codon 129 genotype had an independent effect on log-tau 
in sCJD cases after adjustment for age and gender (β=0.434, 
P=0.004. r2 for model 0.22).
Neurofilament light
NfL concentrations were substantially higher in patients with 
sCJD than in healthy controls: median 296 pg/mL vs 14.5 pg/
mL (Mann-Whitney U test, P<0.001; table 2, figure 1B). Linear 
regression modelling of the effect of diagnosis (sCJD vs control), 
age and gender on log-NfL showed a very strong independent 
effect of sCJD diagnosis after adjustment for age and gender 
(β=0.829, P<0.001. r2 for model 0.873). Age also had an inde-
pendent effect on log-NfL (β=0.158, P=0.004), as has been 
seen in other studies.25 32 Gender did not appear to have an inde-
pendent effect (P=0.074).
NfL concentrations did not vary between patients with sCJD 
with different genotypes at codon 129 (table 2, figure 1D).
Performance of serum tau and NfL as diagnostic markers
Receiver operating characteristic curves for serum tau and NfL 
as diagnostic tests for distinguishing sCJD cases from healthy 
controls are shown in figure 2. Area under the curve for tau 
is 0.905 (95% CI 0.826 to 0.984) and for NfL is 1: all patient 
samples had higher NfL concentrations than all healthy control 
samples.
A recent study by Steinacker et al30 using Simoa to measure the 
same biomarkers proposed diagnostic cut-off values of 2.2 pg/mL 
for serum tau and 44.7 pg/mL for serum NfL for distinguishing 
CJD cases from controls. We have applied these cut-offs to our 
results. For tau, this gives a sensitivity of 91% (95% CI 78.8% to 
Table 2 Median and IQR for serum tau and NfL concentrations in controls and patients with sCJD. Results for sCJD subgroups according to PRNP 
codon 129 genotype are also shown
serum tau (pg/mL) serum NfL (pg/mL)
n Median IQr n Median IQr
Controls 24 1.56 1.32–1.97 24 14.52 8.04–20.36
  sCJD
  Codon 129
All 45 6.22 3.26–19.6 42 296.6 193–436
MM 21 19.6 7.82–47.3 19 305.6 206–480
MV 15 3.27 2.71–5.12 14 215.1 161–374
VV 7 4.05 3.78–17.9 7 350.1 245–472
NfL, neurofilament light; sCJD, sporadic Creutzfeldt-Jakob disease.
Median results (shown in bold) and IQR for serum tau and NfL concentrations in controls and patients with sCJD. Results for sCJD subgroups according to  PRNP  codon 129 
genotype are also shown.  
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97.5%) and specificity of 83% (95% CI 62.6% to 95.3%). For 
NfL, this gives a sensitivity of 100% (95% CI 91.6% to 100%) 
and specificity of 100% (95% CI 85.8% to 100%). This provides 
some independent validation of the diagnostic cut-off values 
suggested in Steinacker et al,30 although it should be noted that 
our current study included only healthy controls.
Correlation with rate of disease progression
The relationship of serum tau and NfL to rate of clinical disease 
progression (quantified as modelled linear slope of func-
tional decline from MRC Scale data, as described in Mead et 
al’s9 study) is shown in figure 3. Log-tau was positively correlated 
with rate of disease progression (modelled MRC Scale linear 
slope): R2=0.552, P<0.001. Log-NfL showed no evidence of 
correlation with rate of disease progression: R2=0.004, P=0.77. 
In the same subset of samples, neither log-tau nor log-NfL 
correlated with age, gender or number of days between sampling 
and patient’s death. Log-tau was correlated with PRNP codon 
129 (as it was in the full sample set—see above), but this was less 
strong (R2=0.3429, P=0.015) than the correlation with rate of 
disease progression.
Testing of serial sample sets from individual patients with 
sCJd
In six patients with serial sample sets available, both tau and NfL 
concentrations appeared to increase over time in three patients 
with multiple samples taken within the final 12 months of their 
illness, and remain stable in two patients with samples taken over 
longer illness durations (figure 4). This is presented as a descrip-
tive, exploratory analysis due to the small number of patients 
and samples. Five of these patients had an MV genotype at PRNP 
codon 129 and one had a VV genotype. It is important to note 
that this is not a representative subset of the overall sCJD group, 
being skewed towards those with a slower disease progression 
and longer clinical durations.9
dIsCussION
We have shown that concentrations of both tau and NfL are 
elevated in the serum of patients with sCJD compared with 
healthy controls. Serum NfL in particular was able to separate 
patients with sCJD and controls completely, with the lowest 
sCJD result more than double the highest control. Serum tau, 
while showing some overlap between patients with sCJD and 
controls, showed a positive correlation with rate of disease 
progression, and variation between PRNP codon 129 genotypes 
Figure 1 serum tau and neurofilament light (NfL) concentrations in healthy controls and patients with sporadic creutzfeldt-Jakob disease (scJD), and in 
different scJD subgroups according to genotype at PRNP codon 129. all results are plotted on a log scale. small circles represent individual sample results 
(average of two duplicate readings for each sample—see the Methods section). Larger circles indicate median values for each group.
Figure 2 Receiver operating characteristic (ROc) curves for serum tau 
(a) and neurofilament light (NfL) (B) as tests for distinguishing patients 
with sporadic creutzfeldt-Jakob disease (scJD) from healthy controls.
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in keeping with this, suggesting that it might provide a quantita-
tive measure of disease activity. We conclude that both of these 
proteins represent potentially valuable blood-based biomarkers 
for sCJD, and warrant further studies to establish whether they 
may have a useful role in early diagnosis of sCJD, the stratifica-
tion of disease subtypes, and in monitoring of disease activity or 
progression, and of response to experimental therapeutic agents.
Our results are closely concordant with those of two other 
recently published studies which used the same assay platform to 
test these proteins in serum or plasma from independent popula-
tions of patients with sCJD and controls.30 31 Both showed eleva-
tion of tau and NfL concentrations in patients with sCJD, and 
one also showed an identical pattern of effects from PRNP codon 
129 in sCJD to that found in our study.31 This common poly-
morphism is a crucial susceptibility, disease-modifying and strain 
selection factor in human prion disease.33 In our study, NfL was 
elevated in all patients irrespective of PRNP codon 129, while 
tau was higher in those with the MM genotype. We were also 
able to investigate correlations with rate of disease progression 
directly, and show that serum tau, but not NfL, was higher in 
those with more rapidly progressing disease.
It is tempting to conclude that higher concentrations of serum 
tau result from rapid neurodegeneration (as seems to be the case 
for CSF tau,28 which has been shown to be strongly correlated 
with serum tau31), raising the possibility that it could provide a 
quantitative marker of disease ‘intensity’. However, other factors 
may contribute. For example, patients in the very end stages of 
their illness at the time of blood sampling were over-represented 
among those with particularly rapid disease progression and in 
the codon 129 MM group, and they contributed many of the 
samples with the highest tau concentrations. It may be that other 
changes occurring in the preterminal phase, such as breakdown 
of blood–brain barrier integrity, account for these high concen-
trations and drive the overall correlation. Adjusting for these 
potential confounding factors will require a much larger study. 
PrPSc type (as defined by Western blotting of protease-resistant 
prion protein (PrP) from brain homogenate) is known to interact 
with PRNP codon 129 genotype as a phenotype modifier in 
sCJD.34 At the time of publication, PrPSc type was only available 
for 40% of patients included in the current study, so it was not 
appropriate for us to include this in our analysis as the number of 
cases with each type would be very small. Again, demonstrating 
Figure 3 Relationship of serum tau (a) and neurofilament light (NfL) 
(B) (shown on log scales) to rate of disease progression (quantified as 
modelled linear slope of functional decline from MRc prion Disease Rating 
scale (MRc scale) data, as described in Mead et al’s9 study). Log-tau was 
positively correlated with rate of disease progression (r2=0.552, p<0.001), 
while log-NfL showed no significant correlation (r2=0.0044, p=0.77).
Figure 4 changes in serum tau (a) and neurofilament light (NfL) (B) 
concentration over time in six individual patients with sporadic creutzfeldt-
Jakob disease (scJD). each line represents an individual patient, and each 
circle a separate sample. Both tau and NfL concentrations appeared to 
increase over time in three patients with multiple samples taken within 
the final 12 months of their illness, and remain stable in two patients with 
samples taken over longer illness durations.
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any effect of PrPSc type on serum tau and NfL over and above 
that of PRNP codon 129 (which we have found has a strongly 
dominant effect on rate of disease progression9) would require 
a larger study.
Our study provides other novel insights. Longitudinal changes 
in tau and NfL in sCJD have not previously been studied, and 
the serial sample sets that we tested, although in a small number 
of patients, show potentially interesting patterns. In patients 
with multiple samples taken within 12 months of death, there 
appeared to be a trend towards increasing concentrations of 
both tau and NfL over this time, raising the possibility of a 
role as biomarkers of disease progression. In two patients with 
relatively prolonged disease duration and samples taken over a 
longer period, the biomarkers appeared to remain quite stably 
elevated throughout this phase of their illnesses. To establish 
whether the biomarkers follow different trajectories in different 
patient subgroups or in different phases of the disease in indi-
vidual patients will require further data from a larger number of 
prospectively studied patients.
NfL concentration was very substantially elevated even in 
patients at an early stage of disease with very mild functional 
impairment, suggesting that it could have a useful role in early 
diagnosis. While obtaining blood samples from patients with 
sCJD prior to the onset of symptoms is rarely possible, carriers 
of PRNP mutations causing inherited forms of prion disease can 
provide blood samples in the presymptomatic phase. In Stein-
acker et al’s recent study, one serum sample from a presymptom-
atic carrier of the P102L PRNP mutation was found to have a 
modestly raised NfL concentration.30 This will certainly warrant 
further investigation, as a biomarker of impending disease onset 
could be extremely valuable in planning therapeutic trials for 
these patients. Results supporting this role for serum NfL have 
recently been presented for Huntington’s disease32 and familial 
Alzheimer’s disease.35
The relatively small size of this study limits the conclusions 
that can be drawn beyond the primary aim of comparing sCJD 
samples and controls. The matching of patient and control 
groups with respect to factors that might influence biomarker 
concentrations was not perfect: in particular, age, which is 
known to affect serum NfL, was lower in the control group than 
in the patients with sCJD. However, the age ranges in cases and 
controls overlapped substantially, and our linear regression anal-
yses showed that differences between controls and patients with 
sCJD remained after adjustment for age.
Clearly, comparing sCJD patient samples with those from 
healthy controls has limited direct relevance to clinical diag-
nosis, as in practice patients must be distinguished from those 
with other diagnoses causing similar clinical presentations. 
This is particularly relevant for biomarkers such as these which 
are likely to behave as surrogate markers of neurodegenera-
tion, and indeed are known to be elevated in several other 
neurodegenerative conditions18 24 36 37 (although not to the 
same levels seen in patients with sCJD in our study), rather 
than being directly related to specific aspects of the pathology 
of sCJD.
We have independently replicated the findings of other 
recent studies,30 31 demonstrating the potential of NfL and tau 
as biomarkers in sCJD, and generated important hypotheses 
that can be tested in a larger sample archive. The availability of 
patient blood samples associated with detailed and contempora-
neous clinical information collected in the context of a systematic 
prospective clinical study will provide a remarkable opportu-
nity to fully explore the factors affecting these biomarkers, and 
define their utility for clinical practice and research.
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